Research Roundup, September 2025

In this month’s roundup, we highlight recent studies and announcements related to eosinophil-associated diseases:

HES Burden

A new JACI Global study highlights the significant daily burden faced by patients with hypereosinophilic syndromes (HES), including impacts on health and quality of life. APFED is proud to have participated in this project, and we thank the patients and families who shared their experiences.
Read the Full Article

---

EGPA: NS-229 Fast Track

The FDA has granted Fast Track designation to NS-229, an investigational JAK1 inhibitor for eosinophilic granulomatosis with polyangiitis (EGPA). This designation is intended to speed development of treatments for serious medical conditions that fulfill an unmet need.
View the Press Release

---

Mepolizumab and Mood

A study of patients enrolled in the Australian Mepolizumab Registry finds that patients with severe eosinophilic asthma taking mepolizumab, alongside reduced oral steroid use, also experienced improvements in depression and anxiety symptoms. The study concludes that “this further highlights the role of biologics in oral steroid stewardship initiatives.”
Read the Article

---

Environmental Risk and EoE

A new study in Frontiers in Allergy looked at whether exposure to particulate matter (PM2.5 and PM10) is linked to eosinophilic esophagitis (EoE). While environmental exposures remain an area of interest in EoE research, these findings suggest that particulate matter may not be a major risk factor.
Read the Full Article

---

Barzolvolimab Phase 2 in EoE

Celldex reported Phase 2 results of barzolvolimab, a mast-cell depleting antibody, in eosinophilic esophagitis (EoE). While the drug met biomarker goals, it did not improve clinical outcomes, suggesting mast cells may not be a key driver in EoE.
Press Release